Literature DB >> 3893522

Leukaemic transformation of engrafted bone marrow cells.

J L Smith, N A Heerema, A J Provisor.   

Abstract

Recurrent leukaemia following bone marrow transplantation is most often due to the regrowth of original host leukaemia cells, but may also be due to the malignant transformation of normal donor marrow cells after transplantation into a leukaemia patient. We report the ninth case of malignant change in cells of donor origin in a 12-year-old boy who was originally diagnosed as having Ph1+ CML. He remained Ph1+ during lymphoid blast crisis. After transplantation with marrow from a cytogenetically normal sister, he relapsed to Ph1- ALL in the female donor cells. The marrow showed a mixed karyotype of 46,XX/46,XX,inv(9)(p12q12). It would appear that, haematologically, the patient showed different manifestations of the same disease state. Cytogenetically, however, the pre- and post-transplant leukaemias were different.

Entities:  

Mesh:

Year:  1985        PMID: 3893522     DOI: 10.1111/j.1365-2141.1985.tb07438.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  4 in total

1.  Fallout, radiation doses near Dounreay, and childhood leukaemia.

Authors:  S C Darby; R Doll
Journal:  Br Med J (Clin Res Ed)       Date:  1987-03-07

Review 2.  Donor cell-derived leukemia after cord blood transplantation and a review of the literature: differences between cord blood and BM as the transplant source.

Authors:  H Shiozaki; K Yoshinaga; T Kondo; Y Imai; M Shiseki; N Mori; M Teramura; T Motoji
Journal:  Bone Marrow Transplant       Date:  2013-09-09       Impact factor: 5.483

Review 3.  Risks and mechanisms of oncological disease following stem cell transplantation.

Authors:  Sergey V Anisimov; Asuka Morizane; Ana S Correia
Journal:  Stem Cell Rev Rep       Date:  2010-09       Impact factor: 5.739

4.  Pediatric donor cell leukemia after allogeneic hematopoietic stem cell transplantation in AML patient from related donor.

Authors:  Lucina Bobadilla-Morales; Helia J Pimentel-Gutiérrez; Alfredo Corona-Rivera; Sergio Gallegos-Castorena; Jenny A Paniagua-Padilla; Citlalli Ortega-de-la-Torre; Fernando Sánchez-Zubieta; Rocio Silva-Cruz; Jorge R Corona-Rivera; Abraham Zepeda-Moreno; Oscar González-Ramella
Journal:  Mol Cytogenet       Date:  2015-01-31       Impact factor: 2.009

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.